← Back to Search

Provider Education Program for Opioid Use Disorder in Pregnant Women (STEPuP Trial)

N/A
Waitlist Available
Led By Elizabeth Krans, MD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Providers-
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year post delivery
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if a provider education program can help increase adoption of evidence-based practices for treating OUD during pregnancy, and improve maternal-child health outcomes.

Who is the study for?
This trial is for prenatal care providers who treat pregnant women with opioid use disorder (OUD). Providers must be English-speaking and work at obstetric sites. While patient data will be used, only a small group of English-speaking pregnant women meeting OUD criteria will be directly involved in interviews.
What is being tested?
The STEPuP intervention is being tested against usual care to see if it improves the adoption of evidence-based treatments for OUD during pregnancy by prenatal providers. The goal is to enhance maternal-child health outcomes through better provider practices.
What are the potential side effects?
Since this trial focuses on education and training programs for healthcare providers rather than direct medical interventions, there are no traditional side effects associated with the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I'm sorry, I need more information to understand the criterion. Can you please provide me with more context or the full criterion?

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year post delivery
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year post delivery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Patient Medication-assisted treatment (MAT) utilization
Provider Provision of Buprenorphine
Secondary study objectives
Breastfeeding Rate
Contraceptive Utilization Rate
Hepatitis C Virus (HCV) Screening Rate
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: STEPuP InterventionExperimental Treatment1 Intervention
STEPuP interventions
Group II: Usual CareActive Control1 Intervention
Standard of Care

Find a Location

Who is running the clinical trial?

University of PittsburghLead Sponsor
1,789 Previous Clinical Trials
16,358,623 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,594 Previous Clinical Trials
3,327,736 Total Patients Enrolled
Elizabeth Krans, MDPrincipal InvestigatorUPMC Magee-Womens Hospital
1 Previous Clinical Trials
400 Total Patients Enrolled
Marian Jarlenski, PhDPrincipal InvestigatorUniversity of Pittsburgh

Media Library

STEPuP Intervention Clinical Trial Eligibility Overview. Trial Name: NCT04527926 — N/A
Pregnancy Research Study Groups: STEPuP Intervention, Usual Care
Pregnancy Clinical Trial 2023: STEPuP Intervention Highlights & Side Effects. Trial Name: NCT04527926 — N/A
STEPuP Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT04527926 — N/A
~73 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top